Evaluation of Protease Inhibition for COVID-19 in Standar... | NCT05011513

NCT05011513

ID	Type	Description	Link
2021-002857-28	EudraCT Number
EPIC-SR	Other Identifier	Alias Study Number

Status Module

Oversight Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
PF-07321332/ritonavir	Experimental	Orally administered PF-07321332+ritonavir	Drug: PF-07321332 Drug: Ritonavir
Placebo	Placebo Comparator	Orally administered Placebo	Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
PF-07321332	Drug	PF-07321332 (tablet)	PF-07321332/ritonavir
Ritonavir

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28	Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was considered as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this outcome measure time to sustained alleviation is reported consolidated for overall COVID-19 signs and symptoms.	From Day 1 to Day 28

Secondary Outcomes

Measure	Description	Time Frame
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation	An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening ; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity ; congenital anomaly/birth defect; or that was considered as an important medical event. TEAEs were defined as events that started on or after the study medication start date and time. AEs included both serious and all non-serious adverse events. AEs that led to study discontinuation and AEs that led to discontinuation of study intervention and then continued study were also reported in this outcome measure.

Eligibility Module

Name	Affiliation	Role
Pfizer CT.gov Call Center	Pfizer	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Cahaba Research Inc		Pelham	Alabama	35124	United States
The Institute for Liver Health dba Arizona Clinical Trials

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
40788441	Derived	Brown TM, Kanu C, Harrington M. Assessing participants' experiences with the COVID-19 symptom diary in a clinical trial. J Patient Rep Outcomes. 2025 Aug 11;9(1):99. doi: 10.1186/s41687-025-00901-5.
40592258	Derived	Baniecki ML, Guan S, Rai DK, Yang Q, Lee JT, Hao L, Weinstein E, Hyde C, Cardin RD, Soares H, Hammond J. Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19. EBioMedicine. 2025 Aug;118:105819. doi: 10.1016/j.ebiom.2025.105819. Epub 2025 Jun 30.

Label	URL
To obtain contact information for a study center near you, click here.	View source

IPD Sharing Statement Module

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Nirmatrelvir 300 Milligram (mg) + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5
FG001	Placebo

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Jun 9, 2022	Jul 20, 2023

Arm/Group Information

ID	Title	Description
BG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
BG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	BG00041.76± 13.47 BG00142.63± 13.13 BG00242.18± 13.31

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000344 BG001352 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG000272 BG001261 BG002

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG00039 BG00132 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28

Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was considered as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this outcome measure time to sustained alleviation is reported consolidated for overall COVID-19 signs and symptoms.

Modified intent-to-treat (mITT1) population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized.

Posted

Median

95% Confidence Interval

Days

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants	OG000654 OG001634

Title

Denominators

Categories

Title	Measurements
	OG00012.000(11.000 to 13.000) OG00113.000(12.000 to 14.000)

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Log Rank		0.6027														Superiority

Secondary

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation

An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening ; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity ; congenital anomaly/birth defect; or that was considered as an important medical event. TEAEs were defined as events that started on or after the study medication start date and time. AEs included both serious and all non-serious adverse events. AEs that led to study discontinuation and AEs that led to discontinuation of study intervention and then continued study were also reported in this outcome measure.

Posted

Count of Participants

Participants

From start of study intervention (Day 1) up to Day 34

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001

Secondary

Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28

Percentage of participants with COVID-19 related hospitalization or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier (KM) method.

Modified Intent-To-Treat (mITT1) population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized.

Posted

Number

Percentage of participants

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants

Secondary

Percentage of Participants With Death Through Week 24

Percentage of participants with death (all-cause) event were reported in this outcome measure.

Posted

Number

Percentage of participants

From Day 1 to Week 24

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants	OG000

Secondary

Number of COVID-19 Related Medical Visits Per Day Through Day 28

Number of COVID-19 related medical visits per day were reported in this outcome measure.

Posted

Least Squares Mean

95% Confidence Interval

Medical visits per day

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants	OG000

Secondary

Duration of Hospitalization and Intensive Care Unit (ICU) Stay Through Day 28

Posted

Mean

Standard Deviation

Days

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants	OG000

Secondary

Percentage of Participants With Severe Signs and Symptoms of COVID-19 Through Day 28

Participants recorded a daily severity rating of their symptom severity over the past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe. A participant with severe score for any targeted symptoms post-baseline was counted as severe. Vomiting and diarrhea each was rated on a 4-point frequency scale where 0 was reported for no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater. Sense of smell and sense of taste each be rated on a 3-point Likert scale where 0 was reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was less than usual, and 2 for no sense of smell/taste.

mITT1 population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

Posted

Number

Percentage of participants

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Secondary

Time to Sustained Resolution of Overall COVID-19 Signs and Symptoms Through Day 28

Sustained resolution was defined as when targeted symptoms are scored as absent for 4 consecutive days. The first day of the 4 consecutive-day period was considered the first event date.

mITT1 population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized. In this outcome measure time to sustained resolution is reported consolidated for overall COVID-19 signs and symptoms. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

Posted

Median

95% Confidence Interval

Days

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts

Secondary

Time to Sustained Alleviation of Each COVID-19 Signs and Symptoms Through Day 28

Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was treated as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this outcome measure time to sustained alleviation is reported for each COVID-19 signs and symptoms.

Posted

Median

95% Confidence Interval

Days

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Secondary

Time to Sustained Resolution of Each COVID-19 Signs and Symptoms Through Day 28

Sustained resolution was defined as when targeted symptoms are scored as absent for 4 consecutive days. The first day of the 4 consecutive-day period was considered the first event date. In this outcome measure time to sustained resolution is reported consolidated for each COVID-19 signs and symptoms.

mITT1 population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized. Here ''Overall Number of Participants Analyzed''=participants evaluable for this outcome measure and ''number analyzed''= participants evaluable at specified time points.

Posted

Median

95% Confidence Interval

Days

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units

Secondary

Percentage of Participants With Progression to Worsening Status of COVID-19 Signs and Symptoms

Participants recorded a daily severity rating of their symptom severity over the past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe. Vomiting and diarrhea was rated on a 4-point frequency scale where 0 is reported for no occurrence, 1 (mild) for 1 to 2 times, 2 (moderate) for 3 to 4 times, and 3 (severe) for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).

Posted

Number

Percentage of participants

From Day 1 to Day 28

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Secondary

Percentage of Participants With Resting Peripheral Oxygen Saturation Greater Than or Equal to (>=) 95% at Day 1 and Day 5

Percentage of participants with a resting peripheral oxygen saturation >=95% were reported in this outcome measure.

mITT1 population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized. Here ''Overall Number of Participants Analyzed''=participants evaluable for this outcome measure and ''number analyzed''= participants evaluable at specified time points.

Posted

Number

Percentage of participants

Day 1 and Day 5

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants

Secondary

Plasma Concentration Versus Time Summary of PF-07321332

Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received. A randomized but not treated participant was excluded from the safety analyses. Here ''Overall Number of Participants Analyzed''=participants evaluable for this outcome measure and ''number analyzed''= participants evaluable at specified time points.

Posted

Mean

Standard Deviation

Nanograms per milliliter

Day 1: 1 hour post dose; Day 5: 0 minutes pre-dose

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.

Units	Counts
Participants	OG000

Secondary

Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Days 3, 5, 10 and 14

Nasal samples were collected to estimate the viral load in participants in terms of logarithm to base 10 (log10) copies per milliliter.

mITT1 population included all participants randomly assigned to study intervention, who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they were randomized. Here ''Overall Number of Participants Analyzed''=participants evaluable for this outcome measure and ''number analyzed''= participants evaluable at specified time points.

Posted

Least Squares Mean

Standard Error

Log 10 copies per milliliter

Baseline, Days 3, 5, 10 and 14

ID	Title	Description
OG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.
OG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.

Units	Counts
Participants

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Nirmatrelvir 300 mg + Ritonavir 100 mg	Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5.	0	654	8	654	120	654
EG001	Placebo	Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5.	1	634	13	634	71	634

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
COVID-19	Infections and infestations	MedDRA v25.0	Non-systematic Assessment	EG0000 affected654 at risk EG0011 affected634 at risk
COVID-19 pneumonia	Infections and infestations	MedDRA v25.0	Non-systematic Assessment	EG0003 affected654 at risk EG0018 affected634 at risk
Pneumonia	Infections and infestations	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0012 affected634 at risk
Pneumonia aspiration	Infections and infestations	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0010 affected634 at risk
Sepsis	Infections and infestations	MedDRA v25.0	Non-systematic Assessment	EG0000 affected654 at risk EG0011 affected634 at risk
Creatinine renal clearance decreased	Investigations	MedDRA v25.0	Non-systematic Assessment	EG0000 affected654 at risk EG0011 affected634 at risk
Hepatic enzyme increased	Investigations	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0010 affected634 at risk
Electrolyte imbalance	Metabolism and nutrition disorders	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0010 affected634 at risk
Colon cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0010 affected634 at risk
Multiple sclerosis relapse	Nervous system disorders	MedDRA v25.0	Non-systematic Assessment	EG0000 affected654 at risk EG0011 affected634 at risk
Osmotic demyelination syndrome	Nervous system disorders	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0010 affected634 at risk
Respiratory distress	Respiratory, thoracic and mediastinal disorders	MedDRA v25.0	Non-systematic Assessment	EG0001 affected654 at risk EG0010 affected634 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Diarrhoea	Gastrointestinal disorders	MedDRA v25.0	Non-systematic Assessment	EG00026 affected654 at risk EG00119 affected634 at risk
Dyspepsia	Gastrointestinal disorders	MedDRA v25.0	Non-systematic Assessment	EG0008 affected654 at risk EG0012 affected634 at risk
Nausea	Gastrointestinal disorders	MedDRA v25.0	Non-systematic Assessment	EG00021 affected654 at risk EG00117 affected634 at risk
Vomiting	Gastrointestinal disorders	MedDRA v25.0	Non-systematic Assessment	EG00011 affected654 at risk EG00111 affected634 at risk
Activated partial thromboplastin time prolonged	Investigations	MedDRA v25.0	Non-systematic Assessment	EG0007 affected654 at risk EG00112 affected634 at risk
Alanine aminotransferase increased	Investigations	MedDRA v25.0	Non-systematic Assessment	EG00014 affected654 at risk EG0018 affected634 at risk
Aspartate aminotransferase increased	Investigations	MedDRA v25.0	Non-systematic Assessment	EG0009 affected654 at risk EG0014 affected634 at risk
Blood thyroid stimulating hormone increased	Investigations	MedDRA v25.0	Non-systematic Assessment	EG0004 affected654 at risk EG0017 affected634 at risk
Fibrin D dimer increased	Investigations	MedDRA v25.0	Non-systematic Assessment	EG0008 affected654 at risk EG0019 affected634 at risk
Dysgeusia	Nervous system disorders	MedDRA v25.0	Non-systematic Assessment	EG00044 affected654 at risk EG0013 affected634 at risk
Headache	Nervous system disorders	MedDRA v25.0	Non-systematic Assessment	EG0006 affected654 at risk EG0019 affected634 at risk

Certain Agreements

ID	Term
D011024	Pneumonia, Viral
D011014	Pneumonia
D012141	Respiratory Tract Infections
D007239	Infections
D014777	Virus Diseases
D018352	Coronavirus Infections
D003333	Coronaviridae Infections
D030341	Nidovirales Infections
D012327	RNA Virus Infections
D008171	Lung Diseases
D012140	Respiratory Tract Diseases

ID	Term
D013844	Thiazoles
D013457	Sulfur Compounds
D009930	Organic Chemicals
D001393	Azoles
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds